These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 28286977)

  • 61. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
    Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
    BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model.
    Delahoussaye AM; Abi Jaoude J; Green M; Fujimoto TN; Molkentine J; Garcia Garcia CJ; Gay JP; Feng N; Marszalek J; Fowlkes N; Taniguchi CM
    BMC Cancer; 2022 Feb; 22(1):174. PubMed ID: 35172762
    [TBL] [Abstract][Full Text] [Related]  

  • 63. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
    Dhir M; Zenati MS; Hamad A; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
    Ann Surg Oncol; 2018 Jul; 25(7):1896-1903. PubMed ID: 29761331
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory analysis of JCOG1407.
    Tezuka S; Ozaka M; Furuse J; Yokoyama M; Uemura K; Sano Y; Nakachi K; Imaoka H; Unno M; Shirakawa H; Shimizu S; Kato N; Kojima Y; Sano K; Kobayashi S; Terashima T; Morizane C; Ikeda M; Ueno M
    Pancreatology; 2024 Sep; 24(6):909-916. PubMed ID: 39060124
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
    Arima S; Kawahira M; Shimokawa M; Ido A; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Fukahori M; Makiyama A; Taguchi H; Honda T; Shibuki T; Mitsugi K; Nio K; Ide Y; Ureshino N; Mizuta T; Shirakawa T; Otsuka T
    Pancreas; 2021 Aug; 50(7):957-964. PubMed ID: 34347735
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
    Gharaibeh M; McBride A; Alberts DS; Erstad B; Slack M; Alsaid N; Bootman JL; Abraham I
    Pharmacoeconomics; 2018 Nov; 36(11):1333-1343. PubMed ID: 29981004
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy.
    Templeton S; Moser M; Wall C; Shaw J; Chalchal H; Luo Y; Zaidi A; Ahmed S
    J Gastrointest Cancer; 2021 Jun; 52(2):529-535. PubMed ID: 32440849
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Updates on first-line therapy for metastatic pancreatic adenocarcinoma.
    Marks E; Saif MW; Jia Y
    JOP; 2014 Mar; 15(2):99-102. PubMed ID: 24618427
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis.
    Latenstein AEJ; Mackay TM; Creemers GJ; van Eijck CHJ; de Groot JWB; Haj Mohammad N; Homs MYV; van Laarhoven HWM; Molenaar IQ; Ten Tije BJ; de Vos-Geelen J; Besselink MG; van der Geest LGM; Wilmink JW;
    Acta Oncol; 2020 Jun; 59(6):705-712. PubMed ID: 32056483
    [No Abstract]   [Full Text] [Related]  

  • 70. FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study.
    Servetto A; Santaniello A; Napolitano F; Foschini F; Marciano R; Cascetta P; Amato AR; Augurio MR; Maresca L; De Placido P; De Placido S; Formisano L; Bianco R
    Future Oncol; 2022 Jul; 18(21):2643-2653. PubMed ID: 35608115
    [No Abstract]   [Full Text] [Related]  

  • 71. Evaluation of the Treatment Duration of Japanese Patients With Pancreatic Cancer in a Real-World Setting Using a Large Hospital Claims Database: The SUISEI Study.
    Ueno H; Shimizu K; Fukui A; Nii M; Koto R; Unno M
    Pancreas; 2024 Jul; 53(6):e492-e500. PubMed ID: 38767967
    [TBL] [Abstract][Full Text] [Related]  

  • 72. FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer: A Brown University Oncology Research Group Phase I Study.
    Safran H; Charpentier KP; Perez K; Mantripragada K; Miner T; DiPetrillo T; Kuritzky B; Apor E; Bishop K; Luppe D; Mitchell K; Rosati K
    Am J Clin Oncol; 2016 Dec; 39(6):619-622. PubMed ID: 26523444
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment.
    Giordano G; Milella M; Landriscina M; Bergamo F; Tirino G; Santaniello A; Zaniboni A; Vasile E; De Vita F; Re GL; Vaccaro V; Giommoni E; Natale D; Conca R; Santini D; Maiorino L; Sanna G; Ricci V; Iop A; Montesarchio V; Procaccio L; Noventa S; Bianco R; Febbraro A; Lonardi S; Tortora G; Sperduti I; Melisi D
    Cancer Med; 2024 Jun; 13(12):e7345. PubMed ID: 38924262
    [TBL] [Abstract][Full Text] [Related]  

  • 74. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
    Conroy T; Hammel P; Hebbar M; Ben Abdelghani M; Wei AC; Raoul JL; Choné L; Francois E; Artru P; Biagi JJ; Lecomte T; Assenat E; Faroux R; Ychou M; Volet J; Sauvanet A; Breysacher G; Di Fiore F; Cripps C; Kavan P; Texereau P; Bouhier-Leporrier K; Khemissa-Akouz F; Legoux JL; Juzyna B; Gourgou S; O'Callaghan CJ; Jouffroy-Zeller C; Rat P; Malka D; Castan F; Bachet JB;
    N Engl J Med; 2018 Dec; 379(25):2395-2406. PubMed ID: 30575490
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.
    Smyth EN; Bapat B; Ball DE; André T; Kaye JA
    Clin Ther; 2015 Jun; 37(6):1301-16. PubMed ID: 25907619
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer.
    Goldstein DA; Krishna K; Flowers CR; El-Rayes BF; Bekaii-Saab T; Noonan AM
    Med Oncol; 2016 May; 33(5):48. PubMed ID: 27067436
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
    Lorgis V; Chauffert B; Gentil J; Ghiringhelli F
    Anticancer Res; 2012 Sep; 32(9):4125-30. PubMed ID: 22993372
    [TBL] [Abstract][Full Text] [Related]  

  • 78. First-line treatment for advanced pancreatic cancer.
    Kothari N; Saif MW; Kim R
    JOP; 2013 Mar; 14(2):129-32. PubMed ID: 23474553
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel.
    Surinach A; Phung T; Abdul-Rahim O; Khushman M
    Curr Oncol; 2020 Apr; 27(2):e222-e225. PubMed ID: 32489272
    [TBL] [Abstract][Full Text] [Related]  

  • 80. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
    N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.